Sirtex Medical Release: Interim Report – Half-Year Ended 31 December 2012
Sirtex Medical Limited (ASX: SRX) today announced half year results that demonstrate another strong financial performance over the reporting period and continued dose sales growth of its SIRSpheres ® microspheres targeted radiotherapy treatment for liver cancers.